Oral difelikefalin reduces moderate-to-severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.
Authors
Guttman-Yassky E, Facheris P, Da Rosa JC, Rothenberg-Lausell C, Duca ED, David E, Estrada Y, Liu Y, Bose S, Chowdhury M, Munera C, Goncalves J, Nograles K, Kim BS, Lebwohl M
Abstract
Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
